APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function
- 17 February 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (581)
- https://doi.org/10.1126/scitranslmed.abd7522
Abstract
The ε4 allele of the apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD) and greatly influences the development of amyloid-β (Aβ) pathology. Our current study investigated the potential therapeutic effects of the anti-human APOE antibody HAE-4, which selectively recognizes human APOE that is co-deposited with Aβ in cerebral amyloid angiopathy (CAA) and parenchymal amyloid pathology. In addition, we tested whether HAE-4 provoked brain hemorrhages, a component of amyloid-related imaging abnormalities (ARIA). ARIA is an adverse effect secondary to treatment with anti–Aβ antibodies that can occur in blood vessels with CAA. We used 5XFAD mice expressing human APOE4+/+ (5XE4) that have prominent CAA and parenchymal plaque pathology to assess the efficacy of HAE-4 compared to an Aβ antibody that removes parenchymal Aβ but increases ARIA in humans. In chronically treated 5XE4 mice, HAE-4 reduced Aβ deposition including CAA compared to a control antibody, whereas the anti–Aβ antibody had no effect on CAA. Furthermore, the anti–Aβ antibody exacerbated microhemorrhage severity, which highly correlated with reactive astrocytes surrounding CAA. In contrast, HAE-4 did not stimulate microhemorrhages and instead rescued CAA-induced cerebrovascular dysfunction in leptomeningeal arteries in vivo. HAE-4 not only reduced amyloid but also dampened reactive microglial, astrocytic, and proinflammatory-associated genes in the cortex. These results suggest that targeting APOE in the core of both CAA and plaques could ameliorate amyloid pathology while protecting cerebrovascular integrity and function.Keywords
Funding Information
- National Institute on Aging (AG062027)
- National Institute on Aging (AG047644)
- National Institute on Aging (2P30AG019610)
- NIH Office of the Director (OD021629)
- National Institute of General Medical Sciences (5T32GM008151)
- National Institute of Neurological Disorders and Stroke (NS103276)
- JPB Foundation
This publication has 51 references indexed in Scilit:
- Open questions for Alzheimer’s disease immunotherapyAlzheimer's Research & Therapy, 2014
- Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapyNature Reviews Neurology, 2013
- Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosisThe Journal of Experimental Medicine, 2012
- Abca1 Deficiency Affects Alzheimer's Disease-Like Phenotype in Human ApoE4 But Not in ApoE3-Targeted Replacement MiceJournal of Neuroscience, 2012
- ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse ModelsScience, 2012
- Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide ClearanceScience Translational Medicine, 2011
- The overlap between neurodegenerative and vascular factors in the pathogenesis of dementiaActa Neuropathologica, 2010
- Cerebrovascular Dysfunction in Amyloid Precursor Protein Transgenic Mice: Contribution of Soluble and Insoluble Amyloid-β Peptide, Partial Restoration via γ-Secretase InhibitionJournal of Neuroscience, 2008
- Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer diseaseJCI Insight, 2008
- Human Apolipoprotein E4 Alters the Amyloid-β 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic ModelJournal of Neuroscience, 2005